SI-BONE-POC

Silica-based Nanobiomedical Approaches for Treatment of Bone Diseases: Proof-of-Concept

Coordinatore	UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Germany [DE]
Totale costo	161˙560 €
EC contributo	149˙366 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2012-PoC
Funding Scheme	CSA-SA(POC)
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-01-01   -   2013-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ  Organization address address: Langenbeckstrasse 1 city: Mainz postcode: 55131 contact info Titolo: Dr. Nome: Uta Cognome: Veith Email: send email Telefono: +49 6131 17 9717 Fax: +49 6131 17 9669	DE (Mainz)	hostInstitution	149˙366.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Silicatein is a unique enzyme from siliceous sponges that is able to catalyze the formation of an inorganic material, silica or “biosilica” which forms the inorganic skeleton of these sponges. Another exceptional property of this protein is its dual function, as we discovered for the first time in the ERC Advanced Grant “BIOSILICA” (Grant no. 268476): silicatein both (i) acts as an enzyme (biosilica formation) and (ii) exhibits structure-forming/guiding activity. Even more important with regard to the biomedical application of silicatein: the product of the enzymatic reaction, biosilica, is osteogenic and biocompatible and allows the formation of a moldable material – the ideal basis for the potential application in bone healing, as we found. Moreover, we demonstrated that biosilica not only increases the expression of bone morphogenic protein 2 (BMP-2), but also modulates the ratio of expression of two proteins, osteoprotegerin (OPG) and RANKL, that are crucial in pathogenesis of osteoporosis. Hence, biosilica has potential in prophylaxis and therapy of osteoporosis, a major health threat worldwide. Measures to prevent the development of osteoporosis have become increasingly important due to the demographic development in many industrialized countries. Our idea arising from the ERC-funded project is to apply the silica-enzymes fused to a hydroxyapatite-binding protein tag for the formation of bioactive biosilica-based scaffold / nanocomposite materials for bone regeneration and repair in osteoporotic patients and patients with related bone diseases. The proposed project aims at bringing this idea to a pre-demonstration stage by conducting a proof of concept and verifying its innovation potential. The potential commercialization opportunities and the IPR position of this idea will be clarified.'